Friday, November 22, 2024
Facebook Linkedin Twitter
HomeTagsRemeGen

RemeGen

Biotechnology

RemeGen’s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

PR Newswire -
RemeGen Co., Ltd. , a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted...
Biotechnology

RemeGen’s Telitacicept and Disitamab Vedotin Enter China’s National Reimbursement Drug List for SLE and Gastric Cancer Treatment

PR Newswire -
RemeGen Co., Ltd., a commercial-ready biotechnology company, announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us